[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1997040854A3 - Conjugues polypeptidiques destines au transport de substances a travers des membranes cellulaires - Google Patents

Conjugues polypeptidiques destines au transport de substances a travers des membranes cellulaires Download PDF

Info

Publication number
WO1997040854A3
WO1997040854A3 PCT/US1997/007335 US9707335W WO9740854A3 WO 1997040854 A3 WO1997040854 A3 WO 1997040854A3 US 9707335 W US9707335 W US 9707335W WO 9740854 A3 WO9740854 A3 WO 9740854A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell membranes
polypeptide conjugates
transporting substances
hydrophilic
lipophilic
Prior art date
Application number
PCT/US1997/007335
Other languages
English (en)
Other versions
WO1997040854A2 (fr
Inventor
James E Summerton
Dwight D Weller
Original Assignee
Antivirals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antivirals Inc filed Critical Antivirals Inc
Priority to EP97923513A priority Critical patent/EP0966303A2/fr
Priority to AU29298/97A priority patent/AU729643B2/en
Priority to CA002252706A priority patent/CA2252706A1/fr
Priority to JP9539221A priority patent/JP2000509394A/ja
Publication of WO1997040854A2 publication Critical patent/WO1997040854A2/fr
Publication of WO1997040854A3 publication Critical patent/WO1997040854A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions polymères permettant l'apport efficace de composés dans des organismes vivants. Les compositions comprennent des polypeptides présentant une solubilité dans des environnements à la fois hydrophiles et lipophiles du fait qu'ils subissent une transition réversible dépendante du pH d'une forme lipophile à pH bas à une forme hydrophile à pH élevé.
PCT/US1997/007335 1996-05-01 1997-04-30 Conjugues polypeptidiques destines au transport de substances a travers des membranes cellulaires WO1997040854A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97923513A EP0966303A2 (fr) 1996-05-01 1997-04-30 Conjugues polypeptidiques destines au transport de substances a travers des membranes cellulaires
AU29298/97A AU729643B2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes
CA002252706A CA2252706A1 (fr) 1996-05-01 1997-04-30 Conjugues polypeptidiques destines au transport de substances a travers des membranes cellulaires
JP9539221A JP2000509394A (ja) 1996-05-01 1997-04-30 細胞膜を横切って物質を輸送するためのポリペプチド結合体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1634796P 1996-05-01 1996-05-01
US60/016,347 1996-05-01
US2860996P 1996-10-23 1996-10-23
US60/028,609 1996-10-23

Publications (2)

Publication Number Publication Date
WO1997040854A2 WO1997040854A2 (fr) 1997-11-06
WO1997040854A3 true WO1997040854A3 (fr) 1998-03-12

Family

ID=26688485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/007335 WO1997040854A2 (fr) 1996-05-01 1997-04-30 Conjugues polypeptidiques destines au transport de substances a travers des membranes cellulaires

Country Status (5)

Country Link
EP (1) EP0966303A2 (fr)
JP (1) JP2000509394A (fr)
AU (1) AU729643B2 (fr)
CA (1) CA2252706A1 (fr)
WO (1) WO1997040854A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032467A2 (fr) * 1997-01-24 1998-07-30 Antivirals, Inc. METHODE ET CONJUGUE DE TRAITEMENT D'INFECTIONS A $i(H. PYLORI)
US6455495B1 (en) * 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
KR20010012809A (ko) 1997-05-21 2001-02-26 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 생체막을 통한 수송을 증진시키는 조성물 및 방법
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
WO2001013957A2 (fr) 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
AU2001271873A1 (en) 2000-07-06 2002-01-21 Avi Biopharma, Inc. Transforming growth factor beta (TGF-beta) blocking agent-treated stem cell composition and method
AU8466501A (en) 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
JP2004523480A (ja) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ， インコーポレイテッド 活性作用物質送達系ならびに活性作用物質の保護および投与方法
CA2428971A1 (fr) * 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. Conjugues d'un agent therapeutique et d'un porteur peptidique
CA2477088A1 (fr) * 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
US20050234002A1 (en) 2004-01-23 2005-10-20 Mourich Dan V Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2006085973A2 (fr) 2004-07-02 2006-08-17 Avi Biopharma, Inc. Technique et compose antibacterien antisens
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
EP1859041B2 (fr) 2005-02-18 2014-11-19 Angiochem Inc. Polypeptides d'aprotinine pour transporter un composé à travers une barriere sang-cerveau
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
EP1915161B1 (fr) 2005-07-13 2017-04-26 Sarepta Therapeutics, Inc. Compose et procede antibacteriens antisens
CA2614687C (fr) 2005-07-15 2016-03-22 Angiochem Inc. Utilisation de polypeptides de l'aprotinine comme vehicules dans des conjugues pharmaceutiques
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
EP1935434A1 (fr) * 2006-12-19 2008-06-25 Novosom AG Construction et utilisation d'éléments améliorant la transfection
CA2718961C (fr) 2008-03-20 2014-12-16 University Of Florida Research Foundation, Inc. Amelioration de nostocytose de lesion de vaisseau et reparation potentielle de cellules souches
EP2143726A1 (fr) * 2008-07-11 2010-01-13 Novosom AG Acide nucléique comprenant des nucleéotides zwitterioniques
AU2009322043A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8592386B2 (en) * 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
JP5797191B2 (ja) 2009-06-05 2015-10-21 １３セラピューティクス， インコーポレイテッド 免疫調節ペプチドおよびその使用
CN107353317A (zh) 2010-05-28 2017-11-17 萨勒普塔医疗公司 具有修饰的亚基间键和/或端基的寡核苷酸类似物
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
BR112014011875B1 (pt) 2011-11-18 2022-01-04 Sarepta Therapeutics, Inc Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos
MX358497B (es) 2012-03-20 2018-08-23 Sarepta Therapeutics Inc Conjugados de acido boronico de analogos de nucleotido.
GB201210358D0 (en) * 2012-06-12 2012-07-25 Polytherics Ltd Complexes
US9687561B2 (en) 2012-08-14 2017-06-27 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3302489A4 (fr) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Procédés et composés pour le traitement de maladies et d'états pathologiques associés aux lymphocytes
US10980892B2 (en) 2015-06-15 2021-04-20 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CA3000868A1 (fr) * 2015-10-07 2017-04-13 Cormedix Inc. Formulation de penetration cutanee a base de taurolidine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
WO1992002255A1 (fr) * 1990-08-03 1992-02-20 Farmitalia Carlo Erba S.R.L. Nouveau segment de liaison pour agents bioactifs
WO1992010212A1 (fr) * 1990-12-05 1992-06-25 Farmitalia Carlo Erba Srl Conjugues d'anthracycline
WO1997033552A1 (fr) * 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Bioprecurseurs de paclitaxel solubles dans l'eau

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
WO1992002255A1 (fr) * 1990-08-03 1992-02-20 Farmitalia Carlo Erba S.R.L. Nouveau segment de liaison pour agents bioactifs
WO1992010212A1 (fr) * 1990-12-05 1992-06-25 Farmitalia Carlo Erba Srl Conjugues d'anthracycline
WO1997033552A1 (fr) * 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Bioprecurseurs de paclitaxel solubles dans l'eau

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ADAMS N W ET AL: "CONTROLLED RELEASE POLYAMINO ACID-DRUG CONJUGATES FOR SUBCUTANEOUS INJECTION.", 198TH ACS (AMERICAN CHEMICAL SOCIETY) NATIONAL MEETING, MIAMI BEACH, FLORIDA, USA, SEPTEMBER 10-15, 1989. IN: ABSTR PAP AM CHEM SOC, VOL. 198, ABSTRACT NO. 113, XP002048430 *
ARCH PHARMACAL RES (SEOUL), VOL. 12, NO. 2, PUBL. 1989, PAGE(S) 88-93. *
BIOLOGICAL ABSTRACTS, vol. BA88, Philadelphia, PA, US; abstract no. 110606, KIM C-K ET AL: "EFFECTS OF MOLECULAR WEIGHTS ON THE PHYSICO-PHARMACEUTICAL PROPERTIES OF POLY-L-GLUTAMIC ACID CYTARABINE CONJUGATES." XP002048437 *
FABRE, ISABELLE ET AL: "Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro", CANCER RES., 1984, VOL. 44, NO. 8, PAGE(S) 3190-5, XP002048435 *
KATO Y ET AL: "ANTI TUMOR ACTIVITY OF 1-BETA-D ARABINOFURANOSYL CYTOSINE CONJUGATED WITH POLY GLUTAMIC-ACID AND ITS DERIVATIVE.", CANCER RES, VOL. 44, NO. 1, PUBL. 1984, PAGE(S) 25-30., XP002048431 *
LI C ET AL: "Development of a highly efficacious water-soluble polymer- taxol conjugate.", PROCEEDINGS OF THE EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN DIEGO, CALIFORNIA, USA, APRIL 12-16, 1997., vol. 38, March 1997 (1997-03-01), pages 258, XP002048436 *
MALLEY A ET AL: "ANTI TIMOTHY IMMUNO GLOBULIN E FORMATION SUPPRESSION WITH ANTIGEN D GLUTAMIC-ACID D LYSINE CO POLYMER.", INT ARCH ALLERGY APPL IMMUNOL, VOL. 63, NO. 1, PUBL. 1980, PAGE(S) 113-120., XP002048428 *
MCCORMICK-THOMSON, L. ANNE ET AL: "Poly(amino acid) copolymers as a potential soluble drug delivery system. 1. Pinocytic uptake and lysosomal degradation measured in vitro", J. BIOACT. COMPAT. POLYM., 1989, VOL. 4, NO. 3, PAGE(S) 242-51, XP002048433 *
MCCORMICK-THOMSON, L. ANNE ET AL: "Poly(amino acid) copolymers as a potential soluble drug delivery system. 2. Body distribution and preliminary biocompatibility testing in vitro and in vivo", J. BIOACT. COMPAT. POLYM., 1989, VOL. 4, NO. 3, PAGE(S) 252-68, XP002048434 *
MORIMOTO Y ET AL: "ANTITUMOR AGENT POLY-AMINO-ACID CONJUGATES AS A DRUG CARRIER IN CANCER CHEMOTHERAPY.", J PHARMACOBIO-DYN, VOL. 7, NO. 9, PUBL. 1984, PAGE(S) 688-698., XP002048432 *
ROSENBLATT, D. S. ET AL: "Differential effects of folinic acid and glycine, adenosine, and thymidine as rescue agents in methotrexate-treated human cells in relation to the accumulation of methotrexate polyglutamates", MOL. PHARMACOL., 1982, VOL. 21, NO. 3, PAGE(S) 718-22, XP002048427 *
ROSENBLATT, DAVID S. ET AL: "Methotrexate polyglutamates in cultured human cells", ADV. EXP. MED. BIOL., 1983, VOL. 163, NO. FOLYL ANTIFOLYL POLYGLUTAMATES, PAGE(S) 275-85, XP002048429 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9314416B2 (en) 2005-03-03 2016-04-19 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof

Also Published As

Publication number Publication date
AU729643B2 (en) 2001-02-08
JP2000509394A (ja) 2000-07-25
EP0966303A2 (fr) 1999-12-29
AU2929897A (en) 1997-11-19
CA2252706A1 (fr) 1997-11-06
WO1997040854A2 (fr) 1997-11-06

Similar Documents

Publication Publication Date Title
WO1997040854A3 (fr) Conjugues polypeptidiques destines au transport de substances a travers des membranes cellulaires
GC0000107A (en) Water - soluble pharmaceutical compositions in an ionic complex an the use thereof.
AU2002350592A1 (en) Ph-sensitive polymer
MXPA01011968A (es) Materiales y procesos para proporcionar pilas de combustibles y membranas activas.
DE68924197D1 (de) Keine Fäden ziehende, feuchtigkeitshärtende Zusammensetzungen.
ZA975533B (en) Cyclosporin-containing pharmaceutical composition.
WO1998005363A3 (fr) Polypeptides possedant un polymere soluble dans l'eau a n-terminal lie par covalence simple
AU5210798A (en) Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
ZA9710071B (en) Pharmaceutical composition.
AU2218397A (en) Particle-loaded membranes as oxidant scavengers
CA2219819A1 (fr) Nouveaux derives de la dolastatine, leur preparation et leur utilisation
CA2125673A1 (fr) Proteine reconnaissant specifiquement une structure d'adn et son utilisation
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
AUPQ017599A0 (en) Adjuvant composition for chemicals used in agriculture
WO2002034202A3 (fr) Composes antioxydants comprenant plusieurs composants, compositions pharmaceutiques contenant ces composes et utilisation de ceux-ci dans la reduction ou la prevention du stress oxydatif
CA2376894A1 (fr) Composition pharmaceutique comprenant une proteine et une ectoine
EP1080724A4 (fr) Compositions destinees a diminuer l'activite mtp
IT1293978B1 (it) Vasca di fermentazione, particolarmente per la vinificazione in rosso.
NO308362B1 (no) 10,13,15-trioksatrisyklo[9.2.1.19.6]pentadekanonderivater, fremgangsmÕte for deres fremstilling og legemidler som inneholder disse forbindelsene
EP0613689A3 (fr) Compositions, contenant des dérivés de l'iodoaniline dans des matériaux de formation de couches, pour visualiser les voies gastro-intestinales.
ZA987412B (en) 3-Arylsuccinamidohydroxamic acids, processes for their preparation, and drugs containing these substances.
EP0630963A3 (fr) Micro-émulsion acide.
WO1999012945A3 (fr) Derives de glycosylamine hydrophobes, compositions a base de ces derives et procedes d'utilisation
WO2003002598A3 (fr) Peptides destines a etre utilises en tant que facteurs de translocation
AU2437195A (en) Reverse osmosis permeate pump

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2252706

Country of ref document: CA

Ref country code: CA

Ref document number: 2252706

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997923513

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997923513

Country of ref document: EP